And, given the common availability of commercial assays, anti-MPO and anti-PR3 titers have been frequently assessed in SLE patients (Nassberger et al., 1990; Cambridge et al., 1994; Manolova et al., 2001; Pan et al., 2008). Here, PRTN3 is linked to systemic lupus erythematosus.